PRGO

Analyst Note: PRGO (Perrigo Company plc)

Date: 2026-06-20 Current Price: $10.25

1. Structural Readiness

• Aggressive/Pre-Breakout Entry: Not recommended as a standalone signal. The "Forming" state implies waiting for the breakout to confirm the structural integrity before committing capital.
• Breakout Level: Not defined in the provided evidence.
• Current Price: $10.25.
• Extension: Not applicable (price is not extending beyond a breakout level).
• ATR Context: Current ATR is 5.3% (High). This indicates elevated volatility, which is within the historical "sweet spot" (4–6%) for structural setups, suggesting the market is pricing in significant movement potential but also risk.

2. Thesis Layer

• Thesis Classification: Tactical / Setup-Led.
• Macro Thesis: There is no named secular thesis attached to this setup as of 2026-06-20.
• Judgment Framework: The investment case must be judged strictly on the quality of the technical setup (the forming coil) and the immediate business fundamentals (margin inflection, cost savings, and product mix) rather than a broad macro narrative. Do not invent a thesis; the conviction rests on the execution of the operational enhancement program and the specific product cycle described in the earnings data.

3. Business Overview

Perrigo Company plc is a leading pure-play self-care company with over a century of history, operating in the Healthcare sector within the Self-Care/Consumer Health industry.

• Business Model: The company operates a dual model:
• Store Brand/Private Label: Perrigo is the leading provider of store brand self-care products in North America for categories including upper respiratory, healthy lifestyle, and women's health. They also serve as a major supplier to Walmart (12.9% of consolidated net sales in 2025).
• Consumer Brands: The company owns and markets branded products, including Opill® (the first OTC birth control pill in the U.S.), Mederma®, Compeed®, and Solpadeine®.
• Geographic Footprint: Operations span North America and Europe (with brands like Compeed®, e llaOne®, and Jungle Formula®).
• Strategic Shift: As of Q1 2026, the company transitioned from a geographic segment reporting structure to a category-based segment view to better align financial disclosures with product offerings.
• Recent Strategic Actions:
• Asset Divestiture: On April 30, 2026, the company completed the sale of its Dermacosmetics Business for up to €332.6 million (€305.6M upfront + €27M contingent).
• Operational Enhancement: An ongoing program is generating cost savings. In the quarter ended May 2026, the program generated >$7M in savings.
• Innovation: The company is driving growth through consumer-centric innovation, with 60% of the benefit expected in the second half of 2026, including the expansion of the Compeed portfolio and new Infant Formula offerings.

4. Archetype and Conviction

• Archetype: Margin Inflector.
• *Fit:* The company is actively executing a multi-year operational enhancement program designed to reduce portfolio complexity and optimize manufacturing. Management expects to achieve $60M–$80M in savings for 2026, with an additional $20M–$40M expected in 2027. The total anticipated gross pre-tax annual run rate savings is $80M–$100M, with the majority achieved in 2026.
• Valuation & Fundamentals Context:
• Headwinds: Management explicitly notes that prior-year manufacturing volume headwinds will result in an unfavorable All-In EPS impact of approximately $0.60 in 2026.
• Guidance: Full-year 2026 guidance is reaffirmed and is expected to be weighted to the second half (65–70% of CORE adjusted EPS in H2 vs. 30–35% in H1).
• Growth Drivers: Store brand share is improving (12 consecutive periods of share improvement; +270 bps in Q1 2026). Innovation is the single largest sales growth contributor for 2026.
• Conviction Stack:
• Thesis Strength: Moderate. The "Margin Inflector" thesis is supported by concrete cost-saving targets and a completed divestiture, but it is offset by known volume headwinds.
• Evidence Quality: High. The evidence is recent (May 2026 earnings and filings) and specific regarding savings targets and guidance.
• Rerating Potential: Dependent on the successful realization of the second-half earnings weight and the full capture of the $60M–$80M savings target.

5. Invalidations, Strengtheners, and Gaps

• Strengtheners: Confirmation of the second-half earnings weight (65–70% of EPS) in the upcoming reports. Further share gains in the store brand portfolio beyond the 270 bps Q1 gain. Successful launch and uptake of the new Infant Formula offerings.
• Gaps in Evidence:
• Specific Price Targets: No specific breakout price or resistance level is provided in the evidence to define the exact "Conservative Entry" or "Breakout Level."
• Debt/Capital Structure: While the sale of Dermacosmetics generated cash, specific details on how this capital is deployed (debt paydown vs. M&A vs. buybacks) are not detailed in the provided snippets.
• Competitive Landscape: No specific data on competitor actions or pricing pressure in the OTC space beyond the share gain metrics.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Operational enhancement program on track for $60M-$80M savings in 2026; Store brand portfolio extended streak to 12 consecutive periods of share improvement; Sale of Dermacosmetics business completed for €305.6M upfront cash; Guidance reaffirmed with earnings weighted to second half. Key risks: Prior year manufacturing volume headwinds causing $0.60 unfavorable EPS impact in 2026; Execution risk on realizing full cost savings; High volatility (5.3% ATR) indicating market uncertainty; Macroeconomic headwinds including inflation and currency fluctuations. Expected path: Management expects results to be weighted to the second half of 2026 as cost savings are realized and new product launches (Infant Formula, Compeed) gain traction. Expected horizon: 6 to 12 months for the second-half earnings inflection to fully materialize and for the technical setup to resolve.